Clinical trial
A Phase 3, Randomized, Double-Blind, Study to Evaluate the Efficacy and Safety of Cefepime-AAI101 Compared to Piperacillin/Tazobactam in the Treatment of Complicated Urinary Tract Infections, Including Acute Pyelonephritis.
NCT03687255 is registered in ClinicalTrials.gov with Allecra as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 3, Randomized, Double-Blind, Study to Evaluate the Efficacy and Safety of Cefepime-AAI101 Compared to Piperacillin/Tazobactam in the Treatment of Complicated Urinary Tract Infections, Including Acute Pyelonephritis.
- Lead sponsor
- Allecra
- Phase
- Phase 3
- Overall status
- Completed
- Start date
- September 24, 2018
- Completion date
- February 15, 2020
- Enrollment
- 1,043 (actual)
- Sites
- 24
Conditions
As the registry lists them; a condition with its own page is linked.